Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells

被引:0
作者
Max Warncke
Maike Buchner
Gudrun Thaller
Anna Dodero
Alla Bulashevska
Dietmar Pfeifer
Jens Timmer
Hendrik Veelken
机构
[1] University Medical Center Freiburg,Department of Hematology/Oncology
[2] University of Freiburg,Department of Physics and Freiburg Center for Data Analysis and Modeling
[3] Leiden University Medical Center,Department of Hematology
来源
Cancer Immunology, Immunotherapy | 2011年 / 60卷
关键词
Idiotype; Lymphoma; Regulatory T cell; FoxP3;
D O I
暂无
中图分类号
学科分类号
摘要
The idiotypes of B cell lymphomas represent tumor-specific antigens. T cell responses induced by idiotype vaccination in vivo are directed predominantly against CDR peptides, whereas in vitro T cells also recognize framework-derived epitopes. To investigate the mechanisms regulating the specificity of idiotype-specific T cells, BALB/c or B10.D2 mice were immunized with mature dendritic cells loaded with H-2Kd-restricted peptides from influenza hemagglutinin, or from shared (J region) or unique (CDR3) structures of the A20 lymphoma idiotype. Antigen-specific T cells were induced in vivo by the CDR3 and influenza epitopes, but not by the J peptide. Gene expression profiling of splenic regulatory T cells revealed vaccination-induced Treg activation and proliferation. Treg activity involved J epitope-dependent IL-10 secretion and functional suppression of peptide-specific effector T cells. Vaccination-induced in vivo proliferation of transgenic hemagglutinin-specific T cells was suppressed by co-immunization with the J peptide and was restored in CD25-depleted animals. In conclusion, Treg induced by a shared idiotype epitope can systemically suppress T cell responses against idiotype-derived and immunodominant foreign epitopes in vivo. The results imply that tumor vaccines should avoid epitopes expressed by normal cells in the draining lymph node to achieve optimal anti-tumor efficacy.
引用
收藏
页码:49 / 60
页数:11
相关论文
共 246 条
[31]  
Engleman EG(2007)A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Immunity 27 145-492
[32]  
Levy R(2008)Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor Cell 133 775-763
[33]  
Hsu FJ(2006)Regulatory T cells and immune tolerance J Exp Med 203 489-636
[34]  
Caspar CB(2002)In vivo sites and cellular mechanisms of T reg cell-mediated suppression Nat Immunol 3 756-413
[35]  
Czerwinski D(2006)Origin of regulatory T cells with known specificity for antigen Blood 107 628-851
[36]  
Kwak LW(2008)Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines Immunity 28 402-7897
[37]  
Liles TM(2006)Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition J Immunol 177 840-1150
[38]  
Syrengelas A(2005)Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells J Immunol 175 7889-141
[39]  
Taidi-Laskowski B(2003)CD18 is required for optimal development and function of CD4+ CD25+ T regulatory cells Nat Med 9 1144-672
[40]  
Levy R(2006)CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation Immunity 25 129-undefined